Skip to main content
. 2015 Mar 2;112(11):E1297–E1306. doi: 10.1073/pnas.1422481112

Fig. 4.

Fig. 4.

s4-IVIg drug candidate shows enhanced anti-inflammatory potency in two different models of arthritis. (A–C) Results from the CAIA arthritis model. (D–G) Results from the K/BxN arthritis model. (A) IVIg dose–response in CAIA. (B and C) Comparison of 0.1 g/kg s4-IVIg with IVIg at 0.1 and 1 g/kg in CAIA dosed prophylactically (on day 1). (C) Mean arthritis score measured at day 10. (D) IVIg dose–response in the K/BxN model. (E and F) Comparison of 0.1 g/kg s4-IVIg with IVIg at 0.1 and 1 g/kg in the K/BxN model dosed in therapeutic mode. Arrows indicate time of dosing for IVIg/s4-IVIg. (F) Mean arthritis score measured at day 10. (G) Representative H&E staining of ankle joints of K/BxN-induced arthritis mice treated with saline, IVIg (1.0 and 0.1 g/kg), and s4-IVIg (0.1 g/kg). Extensive neutrophil infiltration is observed in the saline-treated and 0.1 g/kg IVIg-treated mice, but limited infiltration is observed in the groups treated with IVIg at 1.0 g/kg and s4-IVIg at 0.1 g/kg. ns, Not significant. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.